

Strategy on Patient-Oriented Research



CIHR **IRSC**

Canadian Institutes of
Health Research

Instituts de recherche
en santé du Canada

President's Advisory Board

Mandate: Provided the President of CIHR with high-level strategic advice on patient-oriented research (Paul Hebert, MD seconded to CIHR)

NAME	AFFILIATION
Sally Brown, RN, MHS	CEO, Heart and Stroke Foundation of Canada
Krista Connell, BPT, MHSA	CEO, Nova Scotia Health Research Foundation
Catriona McMahon, MD	VP, Medical Affairs, Astra Zeneca
Roger Palmer, Ph.D.	Dean, School of Public Health, University of Alberta
Brian Postl, MD	President and CEO, Winnipeg Regional Health Authority
Dorothy Pringle, RN, Ph.D.	Former Dean of Nursing, University of Toronto; Executive Lead, Ontario Ministry of Health and Long Term Care Initiative, Health Outcomes for Better Information and Care (HOBIC)
Sarah Prichard, MD	VP, Global Medical Affairs, Baxter International
Jean Rouleau, MD	Dean, Faculty of Medicine, Université de Montréal
Arthur Slutsky, MD	VP, Research, St Michael's Hospital, Toronto
Aubrey Tingle, MD	Past President and CEO, Michael Smith Foundation for Health Research
Susan Zimmerman, LLB, LLM	Executive Director, Interagency Secretariat on Research Ethics, Tri-Council Initiative

Goal:

Improve **health outcomes** through clinical research

Aims:

Enhance **clinical applications** and **economic impact** of health innovations


Provide health professionals and decision-makers with information on how to deliver **high-quality care** and services in a **cost-effective manner**

Implies a **continuum** from:

“first in patients” studies to


how new and old drugs, devices and procedures are integrated into health systems

Bridging valleys between research and outcomes



Definition of Patient-Oriented Research

Scope of definition



Westfall, J. M. et al. JAMA 2007;297:403-406



Four major components of the Strategy on Patient-Oriented Research

1. Improve the research **environment** and **infrastructure**
2. Mechanisms to better **train and mentor** health professionals and non-clinicians
3. Strengthen **organizational, regulatory** and **financial** support for multi-site studies
4. Support **best practices** in health care

Seven “Signature Initiatives” Under Development

*Enhance Patient-Oriented Care
and Improve Clinical Results
through Scientific and
Technological Innovations*

*Support a High-Quality,
Accessible and Sustainable
Health-Care System*

*Reduce Health Inequities of
Aboriginal Peoples and other
Vulnerable Populations*


*Prepare For and Respond To
Existing and Emerging Threats to
Health*

*Promote Health and Reduce the
Burden of Chronic Disease and
Mental Illness*

- ***Clinical Trials
Networks/Support Units***
- ***Personalized Medicine***
- ***Community Based
Primary Health Care***
- ***Pathways to Health
Equity for Aboriginal
Peoples***
- ***Alzheimer’s***
- ***Epigenetics***
- ***Inflammation in Chronic
Disease***

Build Support Units for clinical research networks


When combined, **SUPPORT** units provide the infrastructure and skills for highly specialized Research Networks to identify and tackle key clinical questions:



Establish national infrastructure: multi-disciplinary research networks

Research Networks bring investigators together to build a critical mass of technical and scientific expertise on a national scale to provide leadership and enhance impact.

RESEARCH NETWORKS



- Act as one coordinated group to effectively direct resources in specialty areas (e.g. mental health, primary care).
- Ask central questions to direct pan-Canadian studies most relevant to Canadians.
- Generate evidence or source from previous work and disseminate best practices to the health-care community.
- Mentor and support the training of emerging talent.

Develop Human Capacity for Patient-Oriented Research

- Train **more health professionals** in health-oriented research
- Mentor, develop and support **careers** of researchers
- Train **more non-clinicians** with advanced degrees in core research methodologies
- **Re-engineer career training and salary awards** to build capacity in patient-oriented research for individuals aligned with patient-oriented research networks and support units

- **Streamline ethics review** for multicentre trials
- Adopt a **national template for contracts** and inter-institutional agreements
- Ensure that **GCP standards** meant for industry do not stifle investigator-initiated research efforts
- Develop **national standards of operation** for all clinical research activities

CIHR has worked to develop an overarching patient oriented research strategy

- High level external advisory board
- Extensive stakeholder consultations

Overarching goal: **Improving health outcomes through research**

Two specific aims:

1. Enhance clinical applications and economic impact of health innovations
2. Provide decision makers with information on how to deliver cost effective high quality care

Creating Momentum through Collaborative Efforts and Partnerships

Launch of SPOR

Federal Government
Departments and Agencies

Provincial Governments
Ministries of Health and Innovation

Provincial Health Research
Organizations & Health
Charities

Professional Health
Organizations
ACAHO, AFMC, RCPSC, CNA

Industry

Academic Institutions

Teaching Hospitals

In person:

- 19 university-based meetings
- 3 virtual consultation meetings with nurses
- 1 meeting with 18 health professionals organizations
- 1 meeting with health charities (7 individual charities, plus the Health Charities Coalition of Canada, on behalf of its 27 member charities)

~ 400 individual attendees in total

Web-based survey:

- Nearly 300 respondents


- **Fall 2010: Board reviewed synthesized feedback, and approved the Strategy document in-principle**
- **Document currently being revised in accord with the Board's recommendations**
- **Final document: estimated completion by end of Spring, 2011**

Implementation Steps:

- **Executive Director hired January 1, 2011**
Jocelyn Cook, PhD, MBA
- **Networks Workshop: January, 2011**
- **Support Units Workshop: March, 2011**
- **National Steering Committee**
(“blue ribbon” panel)
 - **Recruitment of members: Spring, 2011**
 - **Expect first meeting – SOON!**

TY, Questions, Comments, Feedback, . . .

Clinical research is a cornerstone of commercialization in the life sciences sector



As a proxy for the whole industry, pharmaceutical clinical research is a high value global opportunity, accounting for \$526.5 million of R&D expenditure in Canada².

Source: 1. US R&D spending by PhRMA member companies. Discovery/basic includes biological screening and pharmacological screening; pre-clinical includes toxicology and safety testing and bioavailability; manufacturing includes synthesis and extraction and process development for manufacturing and quality control. Source: PhRMA Annual Survey, 2002. 2. Table 19: This represents all the clinical trial expenditures for companies with patented-medicines in Phases I-III trials. Source: PMPRB, Current R&D Expenditures by Type of Research, 2009.